Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-001 in Third Molar Extraction
NCT06864884Phase 1Recruiting
- Sponsor
- Arcato Laboratories
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial in acute postoperative pain comparing ARC-001 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at 28 Days. Started Feb 2025; status: recruiting.
02
Drugs
ARC-001
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT06864884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864884.